NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
ANI Pharmaceuticals Inc is a small cap company (market value between $300 million and $2 billion) in the Drug Manufacturers - Specialty & Generic industry.
ANI Pharmaceuticals develops, manufactures, and commercializes therapeutics through three business segments: Rare Disease, Generics, and Brands. The Rare Disease segment includes products like Cortrophin Gel, ILUVIEN, and YUTIQ, while the Brands segment comprises various branded pharmaceuticals including Atacand, Arimidex, and Inderal. The Generics portfolio addresses multiple therapeutic areas.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the ANI Pharmaceuticals Inc stock.
Undervalued: intrinsic value $179.58 per share, market price $72.00, margin of safety 59.9% (as of 2026-10-30).
Discounting its cash flows at 7.6% (average of 3 methods) values the shares at $179.58; the price of $72.00 is 60% below that value, and 82% of that value comes from beyond year five.
Leak Score: 82/100 on 12 of 12 signals (Strong Leak).
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
ANIP is undervalued (as of the 2026-10-30 close). Discounting its cash flows at 7.6% (average of 3 methods) values the shares at $179.58; the price of $72.00 is 60% below that value, and 82% of that value comes from beyond year five.
$179.58 per share (as of the 2026-10-30 close), against a market price of $72.00. That is a margin of safety of 59.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
82 out of 100, which we rate "Strong Leak", on 12 of 12 value investing signals.